Upcoming Login Downtime
We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.
For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Strongbridge Biopharma plc
Headquarters: Trevose, PA, United States of America
Website: N/A
Year Founded: 1996
Status: Acquired
BioCentury | Feb 16, 2023
Management Tracks
Chinook names Oxtoby head of commercial
Plus: Asabys promotes two to partner and updates from Savara, TriNetX, Mahana, Curi Bio and more
BioCentury | Sep 23, 2022
Management Tracks
Third Rock’s Finer becomes Septerna’s full-time CEO
Plus Thieroff-Ekerdt to head clinical development at Cambrian and an update from Curemark
BioCentury | May 19, 2022
Management Tracks
AbbVie’s Pappalardo joins Fresenius as CMO for North America
Plus SOBI’s Batten joins Veru, and updates from FlandersBio, Google Health, Morphic and more
BioCentury | Jan 3, 2022
Regulation
Regulatory Quick Takes: FDA authorizes Pfizer-BioNTech booster for ages 12-15
Plus Novavax gains India EUA, Spero, Leo and more
BioCentury | Nov 19, 2021
Data Byte
New mechanisms enter the Cushing disease pipeline
The fourth disease-modifying therapy is nearing the market
BioCentury | Sep 17, 2021
Management Tracks
Barnett joins Immunovant as CFO
Plus: Celularity, Autolus, Kyverna, AM-Pharma, Saniona and more
BioCentury | May 24, 2021
Finance
May 24 Quick Takes: Neurology play Eliem raises $60M series B; plus Xeris-Strongbridge, CARsgen, Janssen, Abivax and Takeda
Two months after emerging from stealth with $80 million, Eliem Therapeutics Inc. closed a $60 million series B round led by Intermediate Capital Group and RA Capital Management to advance a pipeline
BioCentury | May 14, 2021
Product Development
May 13 Quick Takes: NEA-backed Allay launches to deliver long-lasting non-opioid pain relief; plus Heron, Strongbridge, Incyte
Allay Therapeutics Inc. debuted Thursday with plans to start Phase IIb testing this year of a sustained-relief non-opioid pain therapy that it says is the first compound with clinical data
BioCentury | Feb 17, 2021
Management Tracks
Athersys chair Gil Van Bokkelen steps down; plus Strongbridge, Medical Alley Association, Freeline, AlzeCure, Egetis, Arena and Prime Movers
Regenerative medicine company Athersys Inc. (NASDAQ:ATHX) said Chairman and CEO Gil Van Bokkelen has stepped down. While the company searches for a successor, President and COO William Lehmann will be
BioCentury | Jul 11, 2020
Management Tracks
Andrews joins Akcea as CMO; plus changes at Strongbridge, Abeona, Lyra, Kronos and more
Items per page:
1 - 10 of 24